GLP-1 drugs like Ozempic, Wegovy, and Mounjaro have been wildly successful. But as popular as they are, Americans still have very negative feelings about the people using them. In this month’s Highlight cover story, Dylan Scott explains why ‘Ozempic stigma’ hasn’t gone away, how it’s impacting GLP-1 users, and whether it could begin to fade as more and more people take the drugs. Also in this issue: How to tolerate uncertainty. What rent freezes could mean for renters. Good news about declining road deaths. And the coming AI wealth boom.
Read more How a fringe idea about race took over the Supreme Court
Can knowing less make you happier?
By Shayla Love
The simple idea that helped prevent millions of traffic deaths
By Bryan Walsh
The one thing Ozempic still can’t fix
By Dylan Scott
Coming August 4
How to tolerate uncertainty in a world that’s full of it
By Elizabeth Weingarten
Coming August 5
The truth about rent control
By Marina Bolotnikova
Coming August 5
Rise of the AI-ristocracy
By Sara Herschander
Coming August 6
- The Highlight